Likewise, the EGFR-inhibitor gefitinib showed a markedly less pronounced antiproliferative efficacy in Jurkat cells, and no appreciable effect in the other three T-cell lymphoma cell lines, as compared with 3ClQuin-SAHA. Here, EGFR is linked to T-cell non-Hodgkin lymphoma.